Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2024
0mins
Source: Newsfilter
Q2 2024 Financial Performance: Calliditas Therapeutics reported a record quarter with net revenues of $46.3 million from TARPEYO, achieving operational profitability and updating revenue guidance for 2024 to between $165 million and $185 million.
Key Developments: The company concluded its Phase 3 NefIgArd study, received full approval for Kinpeygo in Europe, and reported positive results from its Phase 2b trial in Primary Biliary Cholangitis (PBC) with setanaxib, alongside a public cash offer from Asahi Kasei for the company's shares.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
